What he is (one line): professor of genetics at Harvard Medical School, author of Lifespan, originator of the information theory of aging, and the scientist whose epigenetic reprogramming work supplies the "reset" component of Longevity escape velocity (LEV) — the most frequent science guest on Moonshots with Peter Diamandis, with six appearances.
Created 2026-09-30 off the end-to-end read of the 2025-06-25 episode (the research archive). Updated 2026-11-16 (weekly check, see How this page stays current).
Why he is in this archive
Gate: a named individual in ≥2 episodes with no page — six appearances as a guest, plus named mentions on moonshots 273, Moonshots #288, Moonshots #290 and Moonshots #293. He was carrying an entire section of Longevity escape velocity (LEV), which is a concept page, not a person page. The material belongs here.
He also sits at the exact junction this archive exists to hold: the guest, the host, the prize and the funding vehicle are all connected, and every connection is disclosed somewhere — just never in the same breath as the claim. See Moonshots: the disclosures ledger.
His model, step by step
Each step keeps its verbatim quote and its timestamp. This is the theory as he states it, not as it is summarised downstream.
- The genome is stable; the epigenome is not. "you get 3.2 billion letters from your mom, 3.2
billion letters from your dad… It doesn't change over the course of your life. So, I like to ask
people like, why do you look different at 20 and 100?" (Moonshots (2025-06-25) — Harvard Prof Reveals Age-Reversing Science to Look & Feel Younger w/ David Sinclair
0:20:00) - Ageing is information loss, not wear and tear. "it's not just wear and tear. We're not just
breaking down… but it's all about information and entropy." (
0:18:21) The compression: "I think of it like a computer and the software gets corrupted over time." (0:19:04) - There is a backup copy — he calls it "the observer", after Claude Shannon. "the observer
keeps a backup copy of the original signal and if you lose it… you can go back and retrieve
what's missing." (
0:29:37) ⚠️ He has not found it. Asked where it lives: "Oh well, the answer is probably. Um, though I'm going to wait to reveal that in detail." (0:26:46) - Three of the four Yamanaka factors (OSK) reset it, safely, reversibly. "we use a set of genes
that are normally only on in embryos. we turn them on in adult tissues" (
0:05:11); the switch is an antibiotic — "you can just take an antibiotic for a few weeks. It's doxycyc." (0:12:28) - Reset the cell and the disease goes away, because ageing is the underlying cause. "glaucoma
is an age-related disease. You make the eye young again in the animal, the disease goes
away." (
0:45:02) ⚠️ This is the largest claim in the model and it is mouse data. - AI collapses the search. "we believe we found the four main levers… inhibit three of
those and push one" (
0:54:44); then virtual docking against all four targets: "normally this docking would be done by hand by a person would take days… now it's just done like this." (0:56:20) Result: "we published six and we're now down to three" cocktails (0:56:52).
What the model is for, in his words: "we're talking about the ability to truly reset the body…
not just slightly, but by 50, 75, 80, 90%." (0:05:00)
What an operator can do with this
Three things, and only three. Everything else on his tapes is a research programme or a personal routine, not an instruction.
- Hold the one dated, judged test and ignore every other year. XPRIZE Healthspan's grand prize is awarded 2030 against a measured functional endpoint (muscle, cognition, immunity). It is the only claim in this lane with a referee and a date. Every other year said on this show is a forecast.
- Separate "reset" from "bridge" before you spend anything. His own answer on what is
available: "what you eat and exercise, those are the two big ones" (
2:06:45). His reset work is not purchasable at any price today. ⚠️ The supplement block is n=1 and unblinded, and its agenda came from a supplement marketing site (see How he is used, below). - Use his falsification answer as a template, not his conclusions. Asked what would disprove his own theory, he answers instantly and specifically (see the next section). That is the move worth copying from him, and it is rarer on this show than any result.
⚠️ None of the above requires capital, access or mobility. Everything else he describes does — the trials are in Boston, the clinics are US-only, and the funding tier discussed on air is $50,000.
★ The thing that distinguishes him on this show: he names his own falsifier
Unprompted, from an audience question, Moonshots (2025-06-25) — Harvard Prof Reveals Age-Reversing Science to Look & Feel Younger w/ David Sinclair 1:47:39–1:48:22:
"What experiment would falsify your epigenetic noise theory of aging?" — *"Oh, yeah. It's easy uh to to disprove a theory. It's it's much harder to prove it… For example, the ice mice. If we had accelerated the epiggenome aging, so changing the methylation pattern, the gene expression, and those mice were normal and didn't look old, then I would have thrown out the theory. But they did look old… the chances that it would fail were 99%."*
On Moonshots #293 an AI persona asked the four-mate panel the same question in general form and got "if some non-human intelligence landed on the White House lawn". The scientist answers with a specific experiment; the forecasters answer with an alien. That contrast is the strongest argument in the archive for reading the practitioner over the panel.
His positions, and where each one stands
| claim | where | status |
|---|---|---|
| On Longevity escape velocity (LEV): "I don't have a number. I'm actually just on the ground working as hard and fast as I can" | Moonshots (2025-06-25) — Harvard Prof Reveals Age-Reversing Science to Look & Feel Younger w/ David Sinclair 0:14:40 |
✅ The defensible position, and the inverse of the forecasters' |
| "I do believe that we could double the human lifespan now" | same, 0:15:32 |
Stated as a belief, not a forecast. Aspiration: investigate |
| "the first person to live to 150 has already been born" | same, 0:15:42 |
Aspiration: investigate. Not testable for decades; he notes he has "taken some flak" for it |
| ER-100 into humans "next year in January hopefully" | same, 0:06:05 |
Close. IND cleared 2026-01-28; first dosing reported June 2026. Slipped months, not years |
| Green monkeys: "it's looking like 95% of the age goes backwards" in the optic nerve | same, 0:09:47 |
🔴 Self-reported and unpublished. Conference presentations only (ARVO 2023, AAO 2024). Do not repeat the 95% |
| A whole-body pill: "imagine in 10 years you just take a pill for 4 weeks and you get younger" | same, 0:13:00 |
Aspiration. The chemical version exists only in cells in a dish (Aging 2023) |
| "a few cents a day, everybody could afford a longevity pill" | same, 1:55:02 |
Aspiration. Reasoning by analogy to the Moderna vaccine and patent expiry |
| "It may be 2026 is the year we learn that age reversal is possible in humans" | moonshots 249 0:12:59 |
Aspiration: investigate. The only human study is a safety trial reading out May 2027 |
| GLP-1s and NAION: "about 20 to 30,000 people in the US a year" waking up blind | moonshots 251 0:04:28 |
🔴 Off. US NAION incidence from all causes is |
| Economics: "a value to the US economy of $86 trillion" for one extra year | Moonshots (2025-06-25) — Harvard Prof Reveals Age-Reversing Science to Look & Feel Younger w/ David Sinclair 0:59:50 |
🔴 Off by ~2.3×. His own paper says US$38 trillion (Scott, Ellison & Sinclair, Nature Aging 2021). He doubts himself on tape — "Wait, we will fact check that" — and nobody does |
| Nattokinase: "up to 95% of plaque got removed in one year", "at least 6,000 units" | same, 2:07:27, 2:08:09 |
🔴 The statistic is inverted (95.4% is an improvement rate among 1,062 participants, retrospective) and the dose advised is below the study's own ineffective arm (3,600 FU; effective arm 10,800 FU). Barred from Gonçalo copy in every form |
| "none of our papers have ever been disproved or had to be retracted or changed their conclusions" | same, 1:50:49 |
Close, with one exception. No retraction found. But the flagship Cell 2023 ICE paper carries a published erratum (2024) and drew a formal published critique with a response. ⚠️ An erratum is normal publishing, not misconduct — say it that way or not at all |
| Taurine does not decline with age ("Eltorine", "just came out in science", by "Raphael Al Dabo") | same, 1:22:08 |
✅ Correct, including the attribution — de Cabo et al., Science, June 2025, the same month the episode aired |
| SL-100 (the chemical cocktail, "v2 of our reprogramming tech") in fast-ageing LAKI mice: "strong protection against frailty & extension of max lifespan by >33%. Some treated mice still alive" | his X post, 2026-10-01, on Christopher Petty's ARDD 2026 talk (Boston, 1–3 Oct) | 🔴 Self-reported, unpublished, pilot. His own follow-up post (2 Oct) says "Early, unpublished data." A journalist in the room (Antonio Regalado, X, 1 Oct) reports median lifespan +15.4%, not statistically significant, "small + unfinished study", cocktail contents not disclosed (IP). The >33% is a maximum-lifespan figure from a few animals still alive. Do not repeat the >33%. Progeroid mice are a disease model, not normal ageing. ⚠️ Lifespan.io's ARDD write-up (27 Oct 2026, secondary) attributes the SL-100 data to his own talk and gives +25% mean, +33% maximum, no n and no significance test. That makes three different headline figures from three sources (max, median, mean), and none of them is published |
The papers behind him
Full table with what each did and did not show is on Longevity escape velocity (LEV) §The papers. In one line: OSK works in mouse eyes (peer-reviewed), is reported to work in monkey eyes (conference data only), and is in a Phase 1 safety trial in human eyes. The pill version is peer-reviewed only in cells in a dish; a mouse pilot (SL-100, progeroid mice) was shown at a conference on 2026-10-01 and is unpublished. Every paper carries a conflict-of-interest statement tying him to Life Biosciences.
His ties, as disclosed on tape
Routed to Moonshots: the disclosures ledger. The short version, all from Moonshots (2025-06-25) — Harvard Prof Reveals Age-Reversing Science to Look & Feel Younger w/ David Sinclair unless noted:
| company / vehicle | tie | verbatim | ts |
|---|---|---|---|
| Life Biosciences | co-founder; ER-100 is its lead asset; raising for Phase 2 | "I work on epigenetic reprogramming at life biosciences" · "we're just raising money to go into our phase 2 study already" | 0:35:19, 0:44:02 |
| Metro Biotech | investor, not controller; publicly dissents from its FDA choice | "it's not my company. I've invested in it" · *"I was not in favor of that."* | 1:15:16, 1:15:47 |
| NMN trials | "like 30 $30 million worth of my money and others" | as quoted | 1:13:26 |
Legandal (name unresolvable in the captions) |
adviser — LNP targeting | "a company that I'm advising called Legandal" | 0:12:05 |
| XPRIZE Healthspan | registered entrant in the prize his interviewer founded and donates to | "We are registered." | 0:30:31 |
| Friends of Sinclair Lab | beneficiary; the vehicle is created on this episode | "joining David who and myself as 50k level donors" | 2:20:33 |
| his partner's supplement | recommends it on air; corrects the host to the harder framing | "Is it uh Serena makes it?" → *"Uh Serena sells it actually."* | 2:10:26 |
| sells nothing himself | stated, and enforced | "I don't I don't currently sell anything." · "my lawyers spend a fair amount of time… on stopping that" | 1:07:00, 1:06:49 |
| Harvard | employer, explicitly fenced | "my thoughts… have nothing to do with Harvard Medical School… and they're not medical advice" | 2:11:16 |
Credit, stated plainly. He discloses more than the panel typically does, and twice against his own interest: naming his disagreement with an investee, and correcting "makes" to "sells" about his partner's product. He is not the disclosure problem on this show.
★ How he is used by the show — and the one structure worth knowing about
On Moonshots (2025-06-25) — Harvard Prof Reveals Age-Reversing Science to Look & Feel Younger w/ David Sinclair his federal funding collapse ("100% of those grants were
terminated", 0:57:55) becomes, 5 minutes later, an on-air fundraising appeal for his Harvard lab
— placed at the middle of the episode, not the end, and repeated in full at the close. That is
where Friends of Sinclair Lab begins: a $50,000 tier buying quarterly access to "what the
investment opportunities are", plus a Coinbase wallet QR for BTC/ETH/stablecoin (2:19:25).
Fifteen months later Moonshots #288 2:19:21 describes it as established and "in the high-end
single-digit millions".
⚠️ Two fences on this, both required.
- The 14-minute personal-protocol block (
1:05:21–1:19:48) took its agenda from NAD.com, a supplement marketing site, which the host flags himself: "I'm not sure how real it is" (1:05:41). It is not a protocol he published. Nothing from it is reproduced here, and this page gives no medical advice. - The host's Life Biosciences interest is self-disclosed on moonshots 249 and moonshots 273 — both ten months or more AFTER this episode, and no filing naming him has been found. Whether he held it in June 2025 is not established. The defensible sentence is narrow: on the episode about Life Biosciences' lead asset, no interest in it is stated by anyone but its co-founder. The sentence that must never be said is that anyone hid anything.
Where it came up
- Moonshots (2025-06-25) — Harvard Prof Reveals Age-Reversing Science to Look & Feel Younger w/ David Sinclair — the deepest appearance, 2h23, read end to end. The theory, the companies, the funding structure, the protocol block, the AMA
- moonshots 249 (2026-04-27) — on stage at an Abundance event; the longevity pill and the timelines
- moonshots 251 (2026-04-28) — audience Q&A; the GLP-1 / NAION answer; AI in the lab
- moonshots 273
1:41:03— named alongside Altos, Retro, NewLimit; the host's Life Bio disclosure - Moonshots #288
2:19:11— the return announced; Friends of Sinclair Lab described - Moonshots #290
0:25:44— Peter raises his work to Martine Rothblatt; she: "we're not tracking uh David's work in particular, but I'm a huge fan" - Moonshots #293
0:27:40,0:56:50— ER-100 used as an LEV exhibit, and the choroideremia answer - Moonshots #unnumbered
1:04:33,1:10:~— the host's gloss on the 8 Oct ER-100 readout ("regaining their eyesight"); Sinclair on the longevity trip - Longevity escape velocity (LEV) — the concept his work is the reset component of
- Moonshots: the disclosures ledger — the ledger
⚠️ Unverified
All quotes are from auto-captioned transcripts; caption mangles are logged in the episode's the research archive. Specifically still open:
Legandal— the advisory tie is real; the company name is not recoverable from the captions.- His partner's surname is not said on tape and is not supplied here.
- His current Life Biosciences board seat is not confirmed. "Co-founder" is confirmed.
- The 2022 and 2023 appearances (EP #18, the AMA, EP #60) are not ingested. Any statement that a position of his is new is bounded to the four appearances on disk.
- The green-monkey 95% and the XPRIZE chemical-cocktail human trial: no peer-reviewed paper and no registry entry found. XPRIZE Healthspan named 20 finalists on 2026-08-11; the 10 Milestone 2 awardees listed on the XPRIZE release include no Sinclair, Harvard or Life Biosciences team; the other 10 finalist names were not found on that page, so whether a Sinclair team is a finalist is not established (Regalado, X, 1 Oct: "Didnt see Sinclair among X Prize finalists").
- SL-100 — contents undisclosed; no preprint or paper found (PubMed, Europe PMC incl. preprints, bioRxiv, the lab's publications page, checked 2026-10-17). The only sources are two X posts (his and a journalist's) and conference coverage.
- "Inflammules" — a new age-associated cell structure his lab reported at ARDD 2026 (via Lifespan.io, 27 Oct, secondary), said to consume NAD through PARP14. Not published: PubMed has 0 records for the term (checked 2026-10-29). The write-up calls the cells both "mammalian" and "yeast", so the model system is not established either.
How this page stays current
Runs with Longevity escape velocity (LEV)'s weekly pull (Mondays); only the steps that differ are listed.
- His return episode, announced on Moonshots #288, gets a full read and a row in His positions.
- PubMed
Sinclair DA[au], last 7 days — plus a check for errata, corrections or expressions of concern on anything in the papers table. That check is why the row at1:50:49exists; it is re-run every week, and it is reported neutrally. - NCT07290244 (ER-100) — status, enrolment, primary completion, posted results.
- Life Biosciences and Metro Biotech news pages — rounds, first-in-human dates, results.
- Close the page: one-line This week, bump
updated:. No medical advice, no dose, no personal protocol, no family colour (feedback public pages are work not private life).
This week (2026-11-16): nothing changed at any primary source. Papers, trial, both companies and the show are where they were on 10 Nov. The new material is all secondary: an explainer, an opinion column and two critical pieces on the 8 Oct readout, plus an undated on-stage interview.
- Window 2026-11-10 → 2026-11-16, primary sources. PubMed
Sinclair DA[au], 9–16 Nov, by entry date: 0 records. By modification date: 5 records (PMIDs 30193097, 28336669, 28329397, 27345396, 25902704), all from 2015–2018. Their metadata could not be opened this run. Errata search instead:Sinclair DA[au]with publication type published erratum or expression of concern, or "correction" in the title, entered 1 Oct–16 Nov, gives 0 (PubMed connector). The 5 are most likely routine index updates, but that is not confirmed record by record. - NCT07290244 (registry API, read 16 Nov): Recruiting; 18 estimated; start 2026-03-02 (actual); primary completion 2027-05 (est.); completion 2032-03 (est.); last update posted 2026-05-19; same three arms. Unchanged. No results section was in the part of the record that was read. The registry still does not reflect the 8 Oct readout.
- Life Biosciences: press-release and In the Media pages opened at the site. On both, the newest item is still 8 Oct. Nothing after it.
- Metro Biotech: press page opened at the site. Its one item is still 2025-04-22.
- Return episode: not aired. The channel RSS feed has 15 entries, 12–16 Nov, including EP #311 (13 Nov). None of the titles or descriptions mentions Sinclair, longevity, Life Biosciences or ER-100.
- Secondary, read from search results only (no page opened):
- Healio (13 Nov, optometry explainer) restates the 8 Oct data: n=3, Dose Level 1, 2 of 3 with >4 dB at ≥28% of points, no control group. It names the trial sites as Mass Eye and Ear and Columbia's Harkness Eye Institute. Nothing new.
- Boston Globe opinion column (12 Nov) restates the same readout.
- Two critical pieces, a Substack post by S.G. Carney (13 Nov) and calfkicker.com (14 Nov), make the same argument: the visual-field test is subjective and improves with practice, and the release does not report the registry's objective measures (OCT and electroretinography). These are critics' claims, logged neutrally. Not carried: their "co-founder and chairman" (his board seat is still unconfirmed, see Unverified) and the "~$240M raised" figure. Neither was checked against a primary source.
- ⚠️ First-dosing date conflict: the Globe column and National Geographic UK (Sept 2026 issue, seen in an upload dated 15 Nov) both put the first injection in April 2026, in Glendale, CA. The company's first-dosing release is dated 9 Jun. That may be the announcement date and not the dosing date. Not resolved. The page keeps "first dosing reported June 2026".
- Boxlife Magazine (13 Nov) reports an on-stage interview in India. The event and date are not given. It attributes to him a pill "in animal testing, in mice and pigs" and a cost target of "a few thousand, then a few hundred". Pigs are new to this page. Unverified. No primary source and no recording found.
- Lifeboat (10 Nov) reposts the 2023 Aging chemical-cocktail paper. That is old work, not new.
- Not checked this run: his X timeline.
- Open programme, prize, grant or call: none new. XPRIZE Healthspan is already in
pipeline.json. No pipeline or operator_guide rows this week.
Previous (2026-11-10): nothing changed at any source in the window. Papers, trial, both companies and the show are all where they were on 4 Nov.
- Window 2026-11-04 → 2026-11-10, primary sources. PubMed
Sinclair DA[au], 3–10 Nov, by entry date: 0 records. By modification date: 15 records, all older papers. Their metadata could not be opened this run, so the errata check was run as a search instead:Sinclair DA[au]with publication type published erratum or expression of concern, or "correction" in the title, entered 1 Oct–10 Nov, gives 0 (all via the PubMed connector). Most likely these are routine index updates, but that is not confirmed record by record. - NCT07290244 (registry API, read 10 Nov): Recruiting; 18 estimated; start 2026-03-02 (actual); primary completion 2027-05 (est.); completion 2032-03 (est.); last update posted 2026-05-19; same three arms (OAG low dose 2×10¹¹ vg/eye, OAG high dose 6×10¹¹ vg/eye, NAION at the selected dose). Unchanged. The registry still does not reflect the 8 Oct readout.
- Life Biosciences: news page opened at the site. Newest press release is still 8 Oct; nothing after it. The "In the Media" tab was read for the first time: its newest item is also 8 Oct (TIME, "Eye Cells May Have Been Rejuvenated for the First Time in People"), then 24 Jul (The Ophthalmologist) and 18 Jun (Axios).
- Metro Biotech: press page opened at the site. Its one item is still 2025-04-22; nothing in 2026.
- Return episode: not aired. The channel RSS feed (15 entries, 6–10 Nov, including EP #309 on 7 Nov) has no Sinclair, longevity or Life Biosciences title or description. EP #308 (4 Nov) is on disk; see its section below. ⚠️ The feed starts on 6 Nov. EP #309 was checked by title and description only, because its transcript is not on disk.
- Secondary: a web sweep found nothing about him dated 4–10 Nov. The newest coverage found is from earlier in 2026.
- EP308 open item, partly resolved: the host's "just reported… first phase data" matches the 8 Oct Life Biosciences release (n=3, Dose Level 1). The "half a million to two million dollars" treatment range and SL100 at "200 dollars per month" have no primary source (search, 10 Nov). Both stay unverified and are not to be repeated.
- Not checked this run: his X timeline.
- Open programme, prize, grant or call: none new. XPRIZE Healthspan is already in
pipeline.json. No pipeline or operator_guide rows this week.
Previous (2026-11-04): nothing changed at any source in the window — papers, trial, both companies and the show are all where they were on 29 Oct.
- Window 2026-10-29 → 2026-11-04, primary sources. PubMed
Sinclair DA[au], 28 Oct–4 Nov, by entry date: 0 records (PubMed connector). By modification date: 6 records, all his (incl. the Nature 2020 vision-reprogramming paper and the 2023 Nat Biotechnol longevity-biotech letter); none carries a new erratum, retraction, expression of concern or correction — the only cross-references are old commentaries, so these are routine index updates (checked via the NCBI esummary API; the connector's metadata call was not permitted this run). - NCT07290244 (registry API, read 4 Nov): Recruiting; 18 estimated; start 2026-03-02 (actual); primary completion 2027-05 (est.); completion 2032-03 (est.); last update posted 2026-05-19; same three arms. Unchanged. The registry still does not reflect the 8 Oct readout.
- Life Biosciences: news page opened at the site. Newest release is still 8 Oct; nothing after it (next items down: 1 Oct presentation announcement, 10 Aug board appointment, 9 Jun first dosing, 8 Apr Series D). Only the press-release tab was read; the "In the Media" tab was not.
- Metro Biotech: press page opened at the site. Its one item is still 2025-04-22; nothing in 2026.
- Return episode: not aired. The channel RSS feed (15 entries, 26 Oct–4 Nov, including EP #306, #307 and #308) has no Sinclair title or description.
- Secondary: a web sweep of the window found nothing about him dated 29 Oct–4 Nov.
- Not checked this run: his X timeline.
- Open programme, prize, grant or call: none new. XPRIZE Healthspan is already in
pipeline.json. No pipeline or operator_guide rows this week.
Previous (2026-10-29): nothing new at the primary sources (papers, trial, either company, the show). The new material is secondary: a fuller account of his ARDD talk and one public panel.
- Window 2026-10-23 → 2026-10-29, primary sources. PubMed
Sinclair DA[au], 22–29 Oct, by entry date: 0 records. By modification date: 0. A wider query (Sinclair David A[au]orSinclair D[au]with a Harvard affiliation): 0. Errata, retractions or expressions of concern entered 1–29 Oct: 0 (all via the PubMed connector). - NCT07290244 (registry API, read 29 Oct): Recruiting; 18 estimated; start 2026-03-02 (actual); primary completion 2027-05 (est.); completion 2032-03 (est.); last update posted 2026-05-19; same three arms. Unchanged. The registry still does not reflect the 8 Oct readout.
- Life Biosciences: news page opened at the site. Newest release is still 8 Oct; nothing after it. Lifespan.io reposted that release on 27 Oct, and several longevity newsletters ran it 25–29 Oct as if it were new. It is the same n=3 readout, not new data. Not carried: newsletter claims that Dose Level 2 dosing is "underway" or "completing". The company has said only that the safety board recommended escalation and that the trial is ongoing.
- Metro Biotech: press page opened at the site. Its one item is still 2025-04-22; nothing in 2026.
- Return episode: not aired. The channel RSS feed (15 entries, 23–29 Oct, including EP #305 and EP #306) has no Sinclair title or description.
- Secondary, read (Lifespan.io, 27 Oct, ARDD 2026 recap by Arkadi Mazin): he presented in person. Three items were new to this page, all unpublished conference data: (1) "inflammules", a structure that forms with ageing and consumes NAD (see Unverified); (2) OSK put into cancer cells and mouse tumours: the cells "slow down and die", and many "regained their cell type identity", with no numbers, cancer types or n; (3) SL-100, which came from an AI screen of "80 billion molecules", protects ALS motor neurons in a dish and gives "a 25% mean and a 33% maximum lifespan increase" in a pilot in progeroid (LAKI) mice. Logged on the SL-100 row. The write-up says nothing about normal mice or brain organoids, so the Endpoints claim from last week stays unverified.
- Secondary, page not opened (McKinsey blog, 28 Oct, "Healthy longevity is having a moment"; timed out twice, so this is from the search index only): a panel moderated by Time's Alice Park. The index quotes him as "Scientists have a responsibility to communicate what the research actually tells us, where the uncertainties remain" and describes the ER-100 work as having "progressed from animal studies to human clinical trials". No number or timeline is attributed to him. The event name and date are unverified.
- Not checked this run: his X timeline.
- Open programme, prize, grant or call: none new. XPRIZE Healthspan is already in
pipeline.json. No pipeline or operator_guide rows this week.
Previous (2026-10-23): nothing new from him, his papers, the trial or either company in the window.
- Window 2026-10-17 → 2026-10-23, primary sources. PubMed
Sinclair DA[au]by entry date, 16–23 Oct: 0 records (PubMed connector). By modification date: 1 record, PMID 11293800 (Genetica 2000, Drosophila heterochromatin genes). That is a namesake from a different lab, not him; it carries no comment or correction. Errata, retractions or expressions of concern on anything in the papers table: 0. Europe PMC incl. preprints, first published 10–23 Oct: 0. - NCT07290244 (registry API, read 23 Oct): Recruiting; 18 estimated; start 2026-03-02 (actual); primary completion 2027-05 (est.); completion 2032-03 (est.); last update posted 2026-05-19; no results. Unchanged.
- Life Biosciences: news page opened at the site. Newest release is still 8 Oct (the ER-100 interim data); nothing after it.
- Metro Biotech: press page opened at the site. Newest item is still 2025-04-22; nothing in 2026.
- Return episode: not aired. The channel RSS feed (15 newest entries, 20–23 Oct, including EP #304 and EP #305) has no Sinclair title. The EP #303 and EP #304 transcripts on disk do not mention him. ⚠️ The feed window does not reach back to 17 Oct; EP #303 is the only episode in that gap, and it is on disk.
- Secondary, not opened (403): Endpoints News (~2 Oct, outside the window) is indexed as saying SL-100 restored youthful gene expression in brain organoids and extended healthy lifespan in normal and progeria mice. That goes further than the progeroid-only pilot logged on 17 Oct. Unverified. The SL-100 row is unchanged until a primary source shows normal-mouse data.
- Not checked this run: his X timeline.
- Open programme, prize, grant or call: none new. XPRIZE Healthspan is already in
pipeline.json. No pipeline or operator_guide rows this week.
Previous (2026-10-17): nothing new from him or the trial in the window; one missed item from 1–2 Oct is logged.
- Window 2026-10-10 → 2026-10-17, primary sources. PubMed
Sinclair DA[au](entry date, 7 days): 0 records. Errata / retraction / expression-of-concern check on anything of his modified since 1 Oct: 0 (both via the NCBI E-utilities API; the PubMed connector was not permitted this run). Europe PMC incl. preprints, 1 Sep–17 Oct: 0. His lab's publications page lists nothing dated 2026. No statement by him on the ER-100 readout found. - NCT07290244 (read from the registry API): Recruiting; 18 estimated; start 2026-03-02 (actual); primary completion 2027-05 (est.); study completion 2032-03 (est.); last update posted 2026-05-19; no results. Unchanged since May. ⚠️ Correction to last week's open item: the registry already carries three arms — OAG low dose 2×10¹¹ vg/eye, OAG high dose 6×10¹¹ vg/eye, and a NAION cohort at the selected dose (3, may expand to 6). "Dose Level 2" is the registered high-dose arm, not a new cohort; nothing needs adding, and the registry's silence since May is the only gap.
- Life Biosciences: news page (opened at the site) has nothing after the 8 Oct release. Its X account, 13 Oct: CSO Sharon Rosenzweig-Lipson's Eyecelerator talk won the People's Choice Award (company post, opened directly). Glaucoma Physician ran a video interview with her dated 12 Oct (secondary; she restates the n=3 safety framing). No new numbers anywhere.
- Metro Biotech: press page opened at the site: last item 2025-04-22 (MIB-725 Phase 1a first dosing). Nothing for 2026. This closes last week's "not checked at its own site" flag.
- Return episode: not aired. The channel RSS feed (15 newest entries, to 17 Oct) has no Sinclair title; the 15 Oct episode mentions him in a chapter only (logged below).
- Missed by the 5 and 11 Oct refreshes, logged now (outside the window, 1–2 Oct): at ARDD 2026 (Boston, Harvard, 1–3 Oct) Christopher Petty of the Sinclair lab presented pilot data on SL-100, the oral chemical-reprogramming cocktail, in LAKI progeroid mice. His X post (1 Oct, opened directly): "strong protection against frailty & extension of max lifespan by >33%. Some treated mice still alive." Regalado (X, 1 Oct, in the room): median lifespan +15.4%, not significant, small unfinished study, contents undisclosed. Row added to His positions. Endpoints News covered it (~2 Oct; paywalled, not opened). Do not repeat the >33%.
- Open programme, prize, grant or call: none new. XPRIZE Healthspan and its FSHD bonus are already in
pipeline.json; ARDD is a conference, not a call. No pipeline or operator_guide rows this week.
Previous (2026-10-11): the first human ER-100 numbers are out, from the company, not a paper.
- Life Biosciences released interim first-in-human data on 2026-10-08 (company release, Boston; the date matches the announced Eyecelerator @ AAO slot; CSO Sharon Rosenzweig-Lipson, PhD, quoted). Three open-angle glaucoma participants, Dose Level 1 (2×10¹¹ vg, single intravitreal dose plus daily oral doxycycline). "Well-tolerated through Day 56 in all three participants"; "no reported dose-limiting toxicities, adverse events of special interest or serious adverse events"; adverse events attributed to procedure, steroid or pre-existing conditions. Humphrey visual fields: improvement in 2 of 3 at Day 56, "≥ 28% of points… > 4 dB improvement" in each of those two. The data safety monitoring board recommended escalating to Dose Level 2 (6×10¹¹ vg).
- ⚠️ How to read it. n=3, open-label, single arm, 56 days, no control, self-reported by the sponsor (not peer-reviewed). The company itself calls the trial one "designed to evaluate safety and tolerability" and the field results "preliminary signals of improvement". Visual-field testing is subject to learning and test-retest variability that an uncontrolled n=3 cannot separate from effect. This is the first human data for the reset claim, and it is a safety readout with a signal, not an efficacy result. On the His positions table, the ER-100 row stays Close; the 2026 "age reversal is possible in humans" row is not moved by this.
- No statement by him found on the readout in the window; his role in the AAO session is not established (unverified). The release is the only primary source; eyewire.news and pharmacally.com carry secondary summaries, not opened in full.
- NCT07290244: Recruiting; 18 estimated; primary completion 2027-05 (estimated); last registry update 2026-05-19; no results posted. The registry has not caught up with the release (unchanged).
Check whether a dose-level-2 cohort is added(resolved 17 Oct: the 6×10¹¹ arm has been in the registry since the start; see This week). - PubMed
Sinclair DA[au], 7 days to 2026-10-11: 0 records. Errata/corrections check on the papers table: nothing new found. - Metro Biotech: searched, nothing found for October 2026 (not checked at its own site; unverified).
- Open programme, prize, grant or call: none found, so no pipeline or operator_guide rows this week.
2026-10-15 episode (Moonshots #unnumbered), checked 16 Oct (company release and trade coverage found by web search; not opened at the company site): Life Biosciences reported interim phase 1 data for ER-100 on 8 Oct: three glaucoma patients, tolerated through day 56; two showed early signs on visual-field tests (over 28% of locations improved by more than 4 dB); open-label; the company says efficacy cannot be established; the safety board cleared dose level 2 (NCT07290244). On tape Peter Diamandis says "phase three is a safety trial" (a slip for phase one) and "two out of the three patients started regaining their eyesight" (1:10:~). "Regaining eyesight" is his gloss, not the company's. Sinclair attended Peter's longevity trip (1:04:33).
Previous (2026-10-05): the 8 Oct presentation was announced (release dated 2026-10-01), no numbers. Previous (2026-09-30): page created from the end-to-end read of the 2025-06-25 episode.
EP308 (Moonshots #308, aired 2026-11-04) — Phase 1 data and SL100, via Peter
Peter Diamandis, AMA Q1 (1:35:44–1:36:36): Sinclair "just reported his the first phase data" on partial epigenetic reprogramming — three of four Yamanaka factors by AAV gene therapy, "half a million to two million dollars for treatment" — and is developing SL100, "three molecules he discovered with the help of artificial intelligence… How much will it cost–200 dollars per month." ❓ All three claims (Phase 1 readout, the $0.5–2M range, SL100 at $200/mo) are the host's rendering, unchecked this run; Sinclair's own announcements should be found before any of it is repeated. The page's standing caution on his claim history applies. Checked 10 Nov: the Phase 1 readout matches the 8 Oct company release. No primary source was found for the $0.5–2M range or for SL100 at $200/month, so both stay ❓.